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Background: Paroxysmal nocturnal haemoglobinuria (PNH)
presents as two major entities: the classical form, predomi-
nantly hemolytic, and a secondary type with marrow failure
and resultant aplastic anaemia (AA-PNH). Currently, the
treatment of choice of the hemolytic variant is eculizumab;
however, the most frequent form of PNH in México is AA-
PNH.
Patients and Methods: Six consecutive AA-PNH patients
with HLA-identical siblings were allografted in two in-
stitutions in México, employing a reduced-intensity condi-
tioning regimen for stem cell transplantation (RIST)
conducted on an outpatient basis.Figure 1. (A) Percent reduction in LN size, reported as sum of the product of LN diame
of WBCs) and blood donor CD3 chimerism for SPN3975 and(C) SPN3431. (D) B cells
molecules and unique IgH clone counts for SPN3975 at time points (D¼day) post allResults: Median age of the patients was 37 years (range
25e48). The patients were given a median of 5.4  106/kg
allogeneic CD34(+) cells, using 1e3 apheresis procedures.
Median time to achieve above 0.5  109/l granulocytes was
21 days, whereas median time to achieve above 20  109/l
platelets was 17 days. Five patients are alive for 330e3150
days (median 1437) after the allograft. The 3150-day overall
survival is 83.3%, whereas median survival has not been
reached, being above 3150 days.
Conclusion: We have shown that hypoplastic PNH pa-
tients can be allografted safely using RIST and that the
long-term results are adequate, the costebeneﬁt ratio of
this treatment being reasonable. Additional studies are
needed to conﬁrm the usefulness of RIST in the treatment
of AA-PNH.
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School of Medicine, Stanford, CAters (SPD), for 4 patients following ibrutinib initiation. (B) CLL MRD (as percent
(excluding the CLL clone) as percent of total PBMC for SPN3975. (E) Total IgH
o-HCT.
